

16 October 2026

Dear Shareholder

Cynata Therapeutics Limited – Pro-Rata Renounceable Entitlement Offer

As announced on 8 October 2026, Cynata Therapeutics Limited (ACN 104 037 372) (**CYP** or the **Company**), is undertaking a pro-rata renounceable entitlement offer in accordance with the terms of the entitlement offer prospectus (**Prospectus**) lodged with ASIC and ASX on 12 October 2026. The Prospectus replaced the original prospectus lodged with ASIC and ASX on 8 October 2026.

Other than as defined in this letter, capitalised terms have the meanings given to them in the Prospectus.

The Entitlement Offer, which is fully underwritten by Caravel Securities Pty Ltd, aims to raise approximately \$913,000 (before costs) and has the following terms:

1. The Entitlement Offer is renounceable and pro-rata to Eligible Shareholders on the basis of three (3) fully paid ordinary shares in the capital of the Company (**New Shares**) for every eight (8) Shares held by those Shareholders at the Record Date of 13 October 2026 at an Offer Price of \$0.01 per New Share.
2. For every three (3) New Shares subscribed for under the Entitlement Offer, Eligible Shareholders will receive one free attaching option (**Option**), on the following terms:
 - a. Option exercise price of \$0.02; and
 - b. Option expiry date 2.5 years after the date of issue.

The funds raised from the Entitlement Offer will be used to pay for professional advisers, Director and consultant fees in furtherance of the Company's strategic objectives and to pay for the costs of the Offers and for working capital purposes.

Ineligible Shareholders

Any Cynata Shareholder who has a registered address outside of Australia, New Zealand and Singapore (**Ineligible Shareholder**) will not be eligible to participate in the Entitlement Offer.

Our records indicate that you are an Ineligible Shareholder, You are not eligible to participate in the Offer, and you will not be sent a copy of the Prospectus. This decision has been made pursuant to ASX Listing Rule 7.7.1(a) after taking into consideration the costs of complying with legal and regulatory requirements in jurisdictions outside of Australia, New Zealand and Singapore compared with the small number of Ineligible Shareholders and the number and value of Shares to which they would otherwise be entitled.

Thank you for your support of Cynata.

Yours sincerely

Dr Geoffrey Brooke
Non-Executive Chair